Our paper is out in Science Immunology! As you can see from the author list, this was truly a team effort and I am so grateful for everyone’s support, especially Marco Ruella for his mentorship. Next stop: continuing my thesis work into clinical translation at Vittoria Bio 🙂

A Penn Medicine - Abramson Cancer Center research team led by Marco Ruella has found that CD5 knockout boosts #CARTcell anti-tumor efficacy, in a preclinical study published in Science Immunology. spr.ly/6013ihrxL

NEW -CD5 deletion enhances the antitumor activity of adoptive T cell therapies in vivo (liquid & solid cancer models) by enhancement of T signaling, cytotoxicity, and persistence. Stellar work by Ruchi Patel Marco Ruella Penn Medicine Science Immunology science.org/doi/10.1126/sc…

Genetic deletion of #CD5 in CAR T cells given to mice led to enhanced expansion, persistence, and anti-tumor effects against a range of preclinical solid and blood #cancer models. Read more in Science #Immunology: scim.ag/7LE

UCLA UC San Francisco City of Hope Dana-Farber A discovery from PICI Investigators Penn has revealed that deleting the CD5 gene in CAR T cells significantly enhances their antitumor activity across multiple cancer types, opening new avenues for more potent and effective immunotherapies. science.org/doi/10.1126/sc… (5/5)

Looking forward to joining Pillar VC Frequency Bio's Cohort 10 next week! Excited to learn more about the biotech startup community.

Patel et al. used the CRISPR-Cas9 system to ablate expression of the TCR-associated T cell inhibitory receptor CD5 from CAR T cells of several specificities and TCR-redirected T cells. bit.ly/4cnT9J7  Ruchi Patel  Marco Ruella Penn Medicine

In a study published in Science Immunology, Penn Medicine researchers identify #CD5 as an immune checkpoint protein & potential target of future cancer therapies ft. Marco Ruella (Penn Medicine - Abramson Cancer Center) tinyurl.com/4nzzy3bs

The effectiveness of #CARTCellTherapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, according to research led by Penn Medicine - Abramson Cancer Center's Dr. Marco Ruella. spr.ly/6012YGdWi

Happy to share my thesis work, now online at bioRxiv. We show that LDB1 organizes Enhancer-Promoter interaction networks and can function independently of cohesin! biorxiv.org/content/10.110…

Very excited to share this work that could not have been done without the help of Soroush Rais-Bahrami, MD, MBA, FACS and Arnab Basu ! Big thank you to The Oncologist for this opportunity!

Looking forward to discussing our latest work on CD5 next week! Register here to join: workcast.com/register?cpak=…

Learn more about the exciting advances in blood cancer and benign hematology research that Penn Medicine and Penn Medicine - Abramson Cancer Center experts will be presenting at the ASH Annual Meeting this weekend. #ASH24 spr.ly/6015txypB

#ASH24 Energy matters! Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate #CARTCell #TCell #tcellrx #immunotherapy Penn Medicine ash.confex.com/ash/2024/webpr…

Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor Marco Ruella and the Ruella Lab for their invaluable support. Excited to delve deeper into this approach!

A simple dietary supplement may provide a new approach to boost #CART cell function – hear more in the #ASH24 Plenary Session today. Marco Ruella Maayan Levy Puneeth Guruprasad spr.ly/6015QKswz

Wild experience to have seen our story shared at the #ASH24 Plenary in San Diego by my wonderful co-lead Shan Liu ! Looking forward to further proving that we can enhance cancer treatment by modulating readily-actionable patient lifestyle factors.

cell.com/molecular-cell… Our paper is now online Molecular Cell. Architectural protein LDB1 drives enhancer connectivity independently of CTCF/cohesin!

Excited to share our latest work on bioRxiv! Using cell-cycle dynamics and NIPBL depletion, we show that long-range enhancer interactions can form de novo without loop extrusion. Alternative mechanisms, including LDB1 and YY1, may play key roles.biorxiv.org/content/10.110…

Exciting news: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Cancer Cell Marco Ruella Alberto Carturan Puneeth Guruprasad Ruchi Patel Yunlin Zhang Guido Ghilardi and my stellar co-author Siena Nason cell.com/cancer-cell/ab…